The Food and Drug Administration has approved Eli Lilly’s GLP‑1 weight‑loss pill, making it the second oral GLP‑1 medication approved specifically for weight loss to enter the evolving obesity drug market.
Breakdown
- FDA approves Eli Lilly's oral weight loss pill, Foundeo
- Foundeo is the first oral GLP-1 not requiring an empty stomach 13s
- Clinical trials showed 7.5-11.2% weight loss with Foundeo 42s
- Foundeo will be available April 6, priced $149-$349/month uninsured 1m 27s
- About 10% stopped highest dose due to gastrointestinal side effects 1m 17s